List of GLP-1 Medications: Every GLP-1 Drug Available in 2026

List of GLP-1 Medications: Every GLP-1 Drug Available in 2026

By Dr. Onikepe Adegbola, MD PhD

The list of GLP-1 medications has grown significantly over the past few years. What started as a diabetes drug class has expanded into one of the most transformative categories in modern medicine — spanning weight loss, cardiovascular protection, kidney disease, and potentially even neurodegenerative conditions. Keeping track of which drugs are available, what they're approved for, and how they compare is genuinely confusing, even for clinicians.

I prescribe from this list daily, so here's a clear, up-to-date breakdown of every GLP-1 medication currently available or in late-stage development.

Currently FDA-Approved GLP-1 Medications

Here's the complete list of GLP-1 drugs with current FDA approval, organized by active ingredient.

Semaglutide

The dominant GLP-1 molecule in both diabetes and weight management.

• Ozempic — Injectable semaglutide for Type 2 diabetes. Doses: 0.25mg, 0.5mg, 1.0mg, 2.0mg weekly. Manufactured by Novo Nordisk.
• Wegovy — Injectable semaglutide for chronic weight management. Doses: 0.25mg, 0.5mg, 1.0mg, 1.7mg, 2.4mg weekly. Also approved for cardiovascular risk reduction in adults with obesity and established cardiovascular disease.
• Rybelsus — Oral semaglutide for Type 2 diabetes. Doses: 3mg, 7mg, 14mg daily. The only currently available oral GLP-1 medication.

Semaglutide is the most studied GLP-1 receptor agonist, with data from the SUSTAIN (diabetes), STEP (obesity), OASIS (oral), and SELECT (cardiovascular) trial programs. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events — a landmark finding that expanded semaglutide's role beyond metabolic medicine.

Tirzepatide (Dual GIP/GLP-1 Agonist)

Technically not a pure GLP-1 agonist — tirzepatide activates both GLP-1 and GIP receptors, which is why it produces greater weight loss than semaglutide in head-to-head trials.

• Mounjaro — Injectable tirzepatide for Type 2 diabetes. Doses: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg weekly. Manufactured by Eli Lilly.
• Zepbound — Injectable tirzepatide for chronic weight management. Same molecule, same doses, different brand name for the weight loss indication.

The SURMOUNT-1 trial showed an average weight loss of 22.5% at the 15mg dose over 72 weeks — the highest ever achieved by any medication. Tirzepatide also demonstrated superiority over semaglutide 2.4mg in the SURPASS trials for diabetes.

Liraglutide

The first widely successful GLP-1 receptor agonist and still in active use.

• Victoza — Injectable liraglutide for Type 2 diabetes. Dose: 0.6mg, 1.2mg, 1.8mg daily. Manufactured by Novo Nordisk.
• Saxenda — Injectable liraglutide for chronic weight management. Dose: 3.0mg daily. Also approved for adolescents aged 12+.

Liraglutide produces more modest weight loss than semaglutide or tirzepatide (approximately 5–8% body weight), but it has the longest safety track record of any GLP-1 and remains useful for specific patient populations.

Dulaglutide

• Trulicity — Injectable dulaglutide for Type 2 diabetes. Doses: 0.75mg, 1.5mg, 3.0mg, 4.5mg weekly. Manufactured by Eli Lilly.

Trulicity was once the most-prescribed GLP-1 in the world. It has largely been overtaken by semaglutide for new prescriptions but remains commonly used, particularly among patients who started it before the semaglutide wave. Weight loss is moderate (3–5%), so it's primarily a diabetes medication.

Exenatide

The original GLP-1 receptor agonist, derived from Gila monster saliva. Seriously.

• Byetta — Injectable exenatide for Type 2 diabetes. Dose: 5mcg or 10mcg twice daily. Manufactured by AstraZeneca.
• Bydureon BCise — Extended-release injectable exenatide. Dose: 2mg weekly.

Exenatide is the grandfather of the GLP-1 class. It's less potent than newer agents and less commonly prescribed for new patients, but it has the longest safety history — nearly two decades of post-marketing data.

Lixisenatide

• Adlyxin — Injectable lixisenatide for Type 2 diabetes. Dose: 10mcg or 20mcg daily. Manufactured by Sanofi.
• Soliqua 100/33 — Fixed-ratio combination of insulin glargine and lixisenatide.

Primarily used in combination with insulin for patients who need both basal insulin and GLP-1 therapy. Limited weight loss effect.

GLP-1 Medications in Late-Stage Development

The pipeline is extraordinary. Several next-generation molecules are in Phase 3 trials with potential to surpass current options.

Retatrutide (Eli Lilly)

A triple agonist — GLP-1, GIP, and glucagon receptor activation. Phase 2 data showed 24.2% weight loss at 48 weeks at the highest dose, the most ever seen in a clinical trial for any obesity medication. Phase 3 trials are ongoing.

Survodutide (Boehringer Ingelheim/Zealand Pharma)

A dual GLP-1/glucagon receptor agonist. Phase 3 trials targeting both obesity and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). Glucagon receptor activation may provide additional benefits for liver fat reduction.

Orforglipron (Eli Lilly)

A non-peptide, oral GLP-1 receptor agonist. Phase 2 data showed up to 14.7% weight loss at 36 weeks. Unlike oral semaglutide, orforglipron has high bioavailability and fewer dosing restrictions. Phase 3 ATTAIN trials ongoing.

CagriSema (Novo Nordisk)

A combination of semaglutide and cagrilintide (an amylin analogue). Phase 3 data showed approximately 22–25% weight loss — approaching surgical levels. This combination represents Novo Nordisk's response to tirzepatide's superior efficacy over semaglutide alone.

GLP-1 Medications Beyond Weight Loss and Diabetes

The list of GLP-1 indications is expanding faster than most people realize. What started as a diabetes drug class is being studied for a remarkable range of conditions.

Cardiovascular Disease

The SELECT trial established that semaglutide 2.4mg reduces major adverse cardiovascular events by 20% in adults with obesity and established cardiovascular disease — even without diabetes. This led to an expanded FDA indication for Wegovy. Cardiovascular outcomes trials for tirzepatide are ongoing.

Kidney Disease

The FLOW trial showed that semaglutide reduced the risk of kidney disease progression by 24% in patients with Type 2 diabetes and chronic kidney disease. GLP-1 agonists appear to protect the kidneys through anti-inflammatory mechanisms and improved metabolic control. This could eventually add chronic kidney disease to the list of GLP-1 indications.

MASH (Metabolic Dysfunction-Associated Steatohepatitis)

Fatty liver disease is an epidemic that tracks closely with obesity. Multiple GLP-1 agonists, particularly those with glucagon receptor activity (survodutide, retatrutide), are being studied for MASH. Semaglutide has already shown histological improvement in liver biopsies — resolution of MASH without worsening fibrosis in a significant percentage of patients.

Neurodegenerative Disease

This is early-stage but fascinating. GLP-1 receptors exist in the brain, and animal studies show neuroprotective effects. Human trials of semaglutide for Alzheimer's disease and Parkinson's disease are underway. We don't have results yet, and I want to be cautious about over-promising. But if even modest neuroprotective effects are confirmed, it changes the calculus for long-term GLP-1 use in ways we haven't fully considered.

Sleep Apnea

Tirzepatide received FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trials. This makes it the first medication approved for obesity-related sleep apnea, where the primary treatment has traditionally been CPAP machines.

Choosing from the GLP-1 List: What Matters

With this many options on the list of GLP-1 medications, selection depends on several factors:

• Primary goal: Weight loss vs. blood sugar control vs. cardiovascular protection
• Delivery preference: Daily injection, weekly injection, or oral tablet
• Insurance coverage: Often determines which medication is accessible regardless of preference
• Tolerability: GI side effects vary by individual — some patients tolerate one GLP-1 better than another
• Cost: Cash-pay prices vary significantly across the class

For weight loss specifically, tirzepatide (Mounjaro/Zepbound) and semaglutide (Wegovy) are the clear frontrunners based on clinical data. I tend to start with whichever one a patient's insurance covers. If neither is covered, the clinical conversation about alternatives gets more complex.

Supporting Your GLP-1 Treatment

Regardless of which GLP-1 medication you and your doctor choose from this list, the physiological effects are similar: reduced appetite, slowed gastric emptying, and altered nutrient absorption. Every patient on a GLP-1 medication should address protein intake, digestive support, and micronutrient needs. The Casa de Sante GLP-1 supplement line was built for exactly this — gut-gentle formulations that work with your medication rather than against it.

Frequently Asked Questions

What is the strongest GLP-1 medication for weight loss?

Based on current clinical trial data, tirzepatide (Zepbound/Mounjaro) at 15mg weekly produces the highest average weight loss among approved medications — approximately 22.5% over 72 weeks. Among pipeline drugs, retatrutide has shown even higher efficacy in Phase 2 trials. However, individual response varies considerably — some patients respond better to semaglutide than tirzepatide, and vice versa.

Are all GLP-1 medications injections?

No. Rybelsus (oral semaglutide) is currently available as a daily tablet. Orforglipron is an oral GLP-1 agonist in Phase 3 trials. The field is actively moving toward oral delivery options, though injectable formulations currently dominate the market and offer higher efficacy at available doses.

Can I switch between different GLP-1 medications?

Yes, under medical supervision. Switching between GLP-1 medications is common — usually due to side effects, insurance changes, or inadequate response. Your doctor will manage the dose conversion and transition period. There's typically no washout period needed when switching within the GLP-1 class.

How do I know which GLP-1 is right for me?

Start with your insurance formulary — coverage often dictates the practical choice. From there, your doctor considers your primary indication (diabetes vs. weight loss), side effect tolerance, delivery preference, and comorbidities. There's no universally "best" GLP-1; there's the best one for your specific situation.